Abstract
AbstractBackgroundPrimary myelofibrosis (PMF) is a clonal hematological myeloproliferative neoplasm distinguished by poor prognosis and reduced life expectancy. This study aimed to detect the overall survival (OS) in patients with PMF and assess the factors affecting clinical outcomes.AimTo assess factors affecting OS in patients with PMF.Design and MethodsA prospective cohort study included 73 patients with PMF. The dynamic international prognostic scoring system (DIPSS) score was calculated for risk stratification. Age, DIPSS score, excess circulating blast,JAK2 V617Fmutation, bleeding, and thrombosis complications were correlated with OS.ResultsThe median age of our participants at diagnosis was 55 years. TheJAK2 V617Fmutation was positive in 26 (35%) patients. Our patients were classified according to the DIPSS score into intermediate-1, with 21 (28.77%); intermediate-2, with 43 (58.9%) patients; and high, with nine (12.33%) patients. The Kaplan–Meier curve was used to calculate time-to-death curves, which were compared by the log-rank tests. The Cox regression test was done to recognize risk factors for the OS. Age and excess peripheral blast cells were negative predictors of survival outcome (P=0.012 and 0.005, respectively).ConclusionAdvanced age and excess peripheral blast cells are predictors of inferior survival outcomes in patients with PMF.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have